,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AADACL3,,ENSG00000188984,Arylacetamide deacetylase like 3,1,12716115-12728759,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,placenta: 1.3,skin: 0.7,Not detected,,
1,ACKR2,"CCBP2, CCR10, CCR9, CMKBR9, D6",ENSG00000144648,Atypical chemokine receptor 2,3,42804752-42887974,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA013819, HPA073493",Enhanced,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,placenta: 22.9,adipose tissue: 5.3,Cell line enhanced,,BEWO: 50.1;HEL: 15.5;SK-BR-3: 21.0
2,ACVRL1,"ACVRLK1, ALK1, HHT, HHT2, ORW2",ENSG00000139567,Activin A receptor like type 1,12,51906908-51923361,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA007041,Approved,,,,,Expressed in all,Tissue enhanced,,placenta: 126.4,lung: 76.4,Cell line enhanced,,ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
3,ADAMTS14,,ENSG00000138316,ADAM metallopeptidase with thrombospondin type 1 motif 14,10,70672803-70762441,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA034605,,,Uncertain,Cytosol,,Mixed,Tissue enhanced,,gallbladder: 10.9;placenta: 11.1,urinary bladder: 4.4,Cell line enhanced,,CAPAN-2: 8.0;K-562: 9.5;RH-30: 5.3;U-138 MG: 8.8
4,ADAMTS15,,ENSG00000166106,ADAM metallopeptidase with thrombospondin type 1 motif 15,11,130448974-130476641,Predicted secreted proteins,Evidence at transcript level,HPA042867,Uncertain,,Approved,Cytosol,"Urothelial cancer:5.63e-5 (unfavourable), Glioma:9.00e-4 (favourable), Lung cancer:9.72e-4 (unfavourable)",Mixed,Tissue enhanced,,adipose tissue: 30.3;placenta: 23.7,breast: 11.0,Cell line enhanced,,ASC diff: 49.3;ASC TERT1: 30.1;EFO-21: 34.5
5,ADAMTS5,"ADAMTS11, ADMP-2",ENSG00000154736,ADAM metallopeptidase with thrombospondin type 1 motif 5,21,26917912-26966513,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,"HPA005661, CAB025996, HPA030906, HPA030908",Approved,,Supported,Nucleoplasm,"Renal cancer:2.46e-4 (unfavourable), Thyroid cancer:8.54e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 42.4,ovary: 24.3,Cell line enhanced,,ASC diff: 26.2;fHDF/TERT166: 12.4;RH-30: 40.0;U-87 MG: 14.5
6,ADAMTS6,ADAM-TS6,ENSG00000049192,ADAM metallopeptidase with thrombospondin type 1 motif 6,5,65148736-65481920,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA043441,Enhanced,,,,,Mixed,Tissue enhanced,,placenta: 2.7,gallbladder: 2.3,Cell line enhanced,,HBF TERT88: 13.0;hTEC/SVTERT24-B: 12.5;TIME: 11.8;U-2197: 15.1
7,ADAMTS9,KIAA1312,ENSG00000163638,ADAM metallopeptidase with thrombospondin type 1 motif 9,3,64515654-64688000,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA028567, HPA028577, HPA028601",Approved,,Approved,Endoplasmic reticulum<br>Vesicles,,Expressed in all,Tissue enhanced,,placenta: 45.1,adipose tissue: 32.1,Cell line enhanced,,RPTEC TERT1: 20.9;SH-SY5Y: 136.2;WM-115: 27.9
8,ADAMTSL4,"DKFZP434K1772, TSRC1",ENSG00000143382,ADAMTS like 4,1,150549369-150560937,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA006279,Approved,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 88.9,lung: 32.3,Cell line enhanced,,ASC TERT1: 64.0;BEWO: 191.0;K-562: 60.1
9,ADCY4,AC4,ENSG00000129467,Adenylate cyclase 4,14,24318349-24335093,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB005070, HPA048344",Approved,,,,"Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 21.1,lung: 11.6,Group enriched,6.0,HUVEC TERT2: 7.8;TIME: 3.1
10,ADGRD1,"DKFZp434B1272, GPR133, PGR25",ENSG00000111452,Adhesion G protein-coupled receptor D1,12,130953907-131141469,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA042395,Uncertain,,Approved,Nucleus<br>Cytosol,Liver cancer:9.27e-4 (unfavourable),Mixed,Tissue enhanced,,placenta: 44.7,lung: 32.4,Cell line enhanced,,BJ: 4.0;fHDF/TERT166: 4.1;HeLa: 6.4;HHSteC: 5.0;HMC-1: 11.4;U-2 OS: 6.6
11,ADGRG6,"FLJ14937, GPR126",ENSG00000112414,Adhesion G protein-coupled receptor G6,6,142301854-142446266,"Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017346,Approved,,,,"Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 67.2,liver: 36.9,Cell line enhanced,,HUVEC TERT2: 133.3;MCF7: 118.0
12,ADRB1,ADRB1R,ENSG00000043591,Adrenoceptor beta 1,10,114044056-114046908,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA067972,Enhanced,,,,,Tissue enriched,Tissue enhanced,,placenta: 45.4,heart muscle: 10.8,Cell line enhanced,,HDLM-2: 6.7;THP-1: 3.2;TIME: 5.0
13,ADRB3,,ENSG00000188778,Adrenoceptor beta 3,8,37962991-37966965,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA061969,Uncertain,,,,,Not detected,Tissue enhanced,,ovary: 8.9;placenta: 3.7,gallbladder: 2.2,Not detected,,
14,AFF2,"FMR2, FRAXE",ENSG00000155966,AF4/FMR2 family member 2,X,148500619-149000663,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA003139,Approved,,,,,Mixed,Tissue enhanced,,epididymis: 14.5;placenta: 21.1,bone marrow: 8.3,Cell line enhanced,,Daudi: 52.9;HL-60: 25.2;U-698: 74.2;U-937: 18.0
15,AGTR1,"AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R",ENSG00000144891,Angiotensin II receptor type 1,3,148697784-148743008,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA003596,Enhanced,,Uncertain,Vesicles,,Group enriched,Tissue enhanced,,placenta: 214.0,liver: 50.9,Cell line enhanced,,ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
16,AIM1,"CRYBG1, ST4",ENSG00000112297,Absent in melanoma 1,6,106360808-106571978,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB026378, HPA030948, HPA030949",Approved,,Approved,Nucleus<br>Microtubules<br>Cytosol,,Expressed in all,Tissue enhanced,,placenta: 107.4,esophagus: 71.3,Mixed,,
17,ANGPTL1,"ANG3, ANGPT3, AngY, ARP1",ENSG00000116194,Angiopoietin like 1,1,178849705-178871052,Predicted secreted proteins,Evidence at protein level,HPA009976,Approved,,,,"Renal cancer:5.11e-4 (favourable), Liver cancer:8.73e-4 (favourable)",Mixed,Tissue enhanced,,placenta: 190.2,smooth muscle: 96.7,Group enriched,18.0,ASC diff: 102.1;ASC TERT1: 41.7;HHSteC: 54.1;HSkMC: 106.7
18,AOC1,"ABP1, DAO",ENSG00000002726,"Amine oxidase, copper containing 1",7,150824627-150861504,"Enzymes, Predicted secreted proteins",Evidence at protein level,"HPA031032, HPA031033",Approved,,,,Prostate cancer:1.71e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 716.9;small intestine: 247.6,duodenum: 183.2,Cell line enhanced,,CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
19,APLN,"apelin, XNPEP2",ENSG00000171388,Apelin,X,129645259-129654937,Predicted secreted proteins,Evidence at transcript level,,,,,,"Renal cancer:9.61e-5 (unfavourable), Cervical cancer:2.92e-4 (unfavourable), Lung cancer:6.09e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)",Group enriched,Tissue enhanced,,placenta: 79.6,lung: 20.8,Cell line enriched,6.0,HUVEC TERT2: 421.2
20,AREG,"AREGB, SDGF",ENSG00000109321,Amphiregulin,4,74445134-74455009,"Cancer-related genes, Predicted membrane proteins",Evidence at protein level,"HPA008720, CAB023519",Approved,,Approved,Mitochondria,"Lung cancer:1.05e-5 (unfavourable), Head and neck cancer:2.61e-5 (unfavourable), Pancreatic cancer:8.32e-5 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 463.5,gallbladder: 119.8,Cell line enhanced,,CACO-2: 310.7;HBEC3-KT: 461.5;hTCEpi: 463.0;hTERT-HME1: 1044.5;MCF7: 315.9
21,ARID3A,"BRIGHT, DRIL1",ENSG00000116017,AT-rich interaction domain 3A,19,925781-975934,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004793, HPA076330",Enhanced,,Supported,Nucleoplasm<br>Vesicles<br>Cytosol,"Pancreatic cancer:1.95e-5 (favourable), Renal cancer:3.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 33.4,testis: 9.7,Cell line enhanced,,BEWO: 199.1;K-562: 85.1
22,ARMS2,"ARMD8, LOC387715",ENSG00000254636,Age-related maculopathy susceptibility 2,10,122454653-122457352,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA067225,Enhanced,,,,,Not detected,Tissue enhanced,,placenta: 2.0;testis: 2.9,ovary: 0.9,Not detected,,
23,ATG9B,"APG9L2, FLJ14885, NOS3AS, SONE",ENSG00000181652,Autophagy related 9B,7,151012209-151024499,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,esophagus: 9.2;placenta: 5.8;skin: 13.5,testis: 3.8,Cell line enhanced,,BEWO: 12.5;CAPAN-2: 3.7
24,ATP12A,"#945, 2, ATP1AL1, HK",ENSG00000075673,ATPase H+/K+ transporting non-gastric alpha2 subunit,13,24680411-24712493,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039526,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 12.7;placenta: 8.2;tonsil: 14.1,skin: 7.1,Not detected,,
25,ATP1A4,ATP1AL2,ENSG00000132681,ATPase Na+/K+ transporting subunit alpha 4,1,160151570-160186977,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:2.20e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 10.2;testis: 18.2;urinary bladder: 8.6,lymph node: 4.1,Group enriched,11.0,BEWO: 19.2;HDLM-2: 48.0;RT4: 49.0
26,BIRC7,"KIAP, ML-IAP, mliap, RNF50",ENSG00000101197,Baculoviral IAP repeat containing 7,20,63235883-63240507,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047850,,,Supported,Nucleus<br>Microtubule organizing center<br>Cytosol,,Tissue enriched,Tissue enhanced,,placenta: 9.2,skin: 2.7,Cell line enhanced,,REH: 32.5;SK-MEL-30: 145.1;U-937: 33.0
27,BMP1,PCOLC,ENSG00000168487,Bone morphogenetic protein 1,8,22164736-22212326,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins",Evidence at protein level,HPA014572,Enhanced,,,,Renal cancer:3.37e-9 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 21.1,smooth muscle: 10.5,Mixed,,
28,BMP5,,ENSG00000112175,Bone morphogenetic protein 5,6,55753645-55875564,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,placenta: 102.6,prostate: 24.1,Group enriched,9.0,AF22: 27.4;U-2 OS: 22.4
29,BMP6,"VGR, VGR1",ENSG00000153162,Bone morphogenetic protein 6,6,7726797-7881422,Predicted secreted proteins,Evidence at protein level,"CAB002773, HPA062683",Approved,,Approved,Mitochondria,Breast cancer:6.45e-4 (favourable),Expressed in all,Tissue enhanced,,placenta: 33.4,lung: 10.4,Cell line enhanced,,HUVEC TERT2: 162.0;Karpas-707: 72.0;SiHa: 90.3;TIME: 73.2
30,C17orf58,,ENSG00000186665,Chromosome 17 open reading frame 58,17,67991101-67996431,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA023036,Uncertain,,Approved,Plasma membrane<br>Cytosol,"Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 50.5,"cervix, uterine: 42.4",Expressed in all,,
31,C1QTNF6,"CTRP6, ZACRP6",ENSG00000133466,C1q and tumor necrosis factor related protein 6,22,37180167-37199385,Predicted intracellular proteins,Evidence at protein level,HPA002042,Enhanced,,Approved,Nucleus,"Renal cancer:0.00e+0 (unfavourable), Lung cancer:9.60e-6 (unfavourable)",Expressed in all,Tissue enhanced,,endometrium: 52.3;placenta: 41.4,gallbladder: 13.5,Cell line enhanced,,MCF7: 83.4;RT4: 39.7
32,C20orf202,,ENSG00000215595,Chromosome 20 open reading frame 202,20,1203454-1208274,Predicted intracellular proteins,Evidence at transcript level,HPA042786,Uncertain,,,,,Mixed,Tissue enhanced,,placenta: 4.9,lung: 1.9,Not detected,,
33,C2orf83,DKFZp547H025,ENSG00000042304,Chromosome 2 open reading frame 83,2,227610090-227633320,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA030319,Approved,,,,,Not detected,Tissue enhanced,,placenta: 2.9,testis: 0.9,Cell line enhanced,,U-2197: 1.4
34,CADM3,"BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1",ENSG00000162706,Cell adhesion molecule 3,1,159171609-159203313,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA002981, CAB025746",Enhanced,,,,"Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 278.5;placenta: 113.9,"cervix, uterine: 44.7",Group enriched,7.0,HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
35,CAPN6,"CalpM, CANPX, CAPNX",ENSG00000077274,Calpain 6,X,111245103-111270523,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040383,,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,epididymis: 255.9;placenta: 117.0;seminal vesicle: 100.4,endometrium: 37.2,Group enriched,9.0,HAP1: 3.4;HDLM-2: 9.9;NTERA-2: 16.1
36,CCDC102B,"ACY1L, AN, C18orf14, FLJ23594, HsT1731",ENSG00000150636,Coiled-coil domain containing 102B,18,68715209-69055189,Predicted intracellular proteins,Evidence at protein level,"HPA040623, HPA048194",Approved,,Approved,Mitochondria<br>Cytosol,Renal cancer:2.90e-6 (unfavourable),Mixed,Tissue enhanced,,placenta: 41.0,gallbladder: 21.6,Cell line enhanced,,ASC TERT1: 10.0;BJ hTERT+: 23.3;fHDF/TERT166: 20.3;HSkMC: 11.2
37,CCDC68,SE57-1,ENSG00000166510,Coiled-coil domain containing 68,18,54901509-54959508,Predicted intracellular proteins,Evidence at protein level,"HPA040865, HPA048197",Supported,,Approved,Golgi apparatus<br>Cytosol,"Cervical cancer:4.50e-4 (unfavourable), Renal cancer:5.28e-4 (favourable)",Mixed,Tissue enhanced,,placenta: 46.2,small intestine: 27.3,Cell line enhanced,,HHSteC: 11.3;HSkMC: 10.8;TIME: 22.8
38,CCNE1,CCNE,ENSG00000105173,Cyclin E1,19,29811898-29824308,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB000308, CAB016682, HPA018169",Approved,,Enhanced,Nucleoplasm,"Endometrial cancer:6.35e-6 (unfavourable), Liver cancer:3.89e-5 (unfavourable), Ovarian cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 44.6,testis: 22.5,Expressed in all,,
39,CD28,,ENSG00000178562,CD28 molecule,2,203706475-203738912,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA070003,Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 32.4;placenta: 20.9,appendix: 18.6,Group enriched,12.0,Karpas-707: 257.5;RPMI-8226: 118.2;U-266/70: 222.7;U-266/84: 196.1
40,CDH5,"7B4, CD144",ENSG00000179776,Cadherin 5,16,66366622-66404786,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB028366,Approved,,,,Renal cancer:5.14e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 335.1,lung: 120.5,Group enriched,5.0,HUVEC TERT2: 616.7;TIME: 522.0
41,CDKN1C,"BWCR, BWS, KIP2, P57",ENSG00000129757,Cyclin dependent kinase inhibitor 1C,11,2883213-2885881,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA002924,Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Expressed in all,Tissue enhanced,,placenta: 202.5,adipose tissue: 62.5,Cell line enhanced,,HeLa: 21.7;SH-SY5Y: 31.6;SiHa: 21.0
42,CLDN6,,ENSG00000184697,Claudin 6,16,3014712-3020071,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Endometrial cancer:2.42e-6 (unfavourable), Urothelial cancer:1.78e-4 (unfavourable)",Group enriched,Tissue enhanced,,placenta: 1.0;testis: 1.7,"cerebral cortex,lung: 0.3",Group enriched,8.0,BEWO: 460.1;CACO-2: 110.7;NTERA-2: 441.6
43,CNTN5,"hNB-2, NB-2",ENSG00000149972,Contactin 5,11,99020953-100358885,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA039492, HPA041223",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 2.6;placenta: 3.4;thyroid gland: 3.0,fallopian tube: 1.8,Not detected,,
44,COL15A1,,ENSG00000204291,Collagen type XV alpha 1 chain,9,98943179-99070792,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA017913, HPA017915",Enhanced,,Approved,Endoplasmic reticulum,"Urothelial cancer:3.08e-4 (unfavourable), Liver cancer:5.47e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 312.1,smooth muscle: 146.2,Cell line enhanced,,BJ: 21.5;BJ hTERT+: 42.8;HDLM-2: 21.5;U-2197: 40.3;WM-115: 29.2
45,COL21A1,,ENSG00000124749,Collagen type XXI alpha 1 chain,6,56056590-56394094,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA031212,,,Supported,Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 36.7;placenta: 39.0",endometrium: 19.6,Cell line enhanced,,ASC TERT1: 15.7;BEWO: 7.2;HSkMC: 16.7
46,COL4A1,,ENSG00000187498,Collagen type IV alpha 1 chain,13,110148963-110307149,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB001695, HPA054039",Approved,,Uncertain,Nucleoplasm<br>Cytosol,"Renal cancer:1.30e-7 (unfavourable), Cervical cancer:4.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 1237.0,smooth muscle: 436.3,Cell line enhanced,,ASC diff: 355.1;EFO-21: 845.9
47,COL4A2,"DKFZp686I14213, FLJ22259",ENSG00000134871,Collagen type IV alpha 2 chain,13,110305812-110513027,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB010751, HPA029118",Enhanced,,Supported,Vesicles,"Renal cancer:3.49e-5 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 829.9,smooth muscle: 401.0,Cell line enhanced,,EFO-21: 1032.9;WM-115: 470.6
48,COL5A3,,ENSG00000080573,Collagen type V alpha 3 chain,19,9959561-10010471,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA048256,Approved,,,,"Renal cancer:7.17e-8 (unfavourable), Urothelial cancer:6.87e-5 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 47.7,adipose tissue: 30.9,Cell line enhanced,,ASC TERT1: 27.4;BJ: 20.0;BJ hTERT+: 21.4;HSkMC: 20.6;WM-115: 25.9
49,COLEC12,"CL-P1, SCARA4, SRCL",ENSG00000158270,Collectin subfamily member 12,18,316740-500722,Predicted membrane proteins,Evidence at protein level,"HPA047917, HPA071056",Enhanced,,Approved,Golgi apparatus<br>Vesicles<br>Cell Junctions,Thyroid cancer:8.10e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 28.2,lung: 16.7,Cell line enhanced,,ASC TERT1: 16.8;BJ: 10.3;HSkMC: 14.5;U-2197: 29.2
50,CRH,"CRF, CRH1",ENSG00000147571,Corticotropin releasing hormone,8,66176382-66178725,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA046846, HPA062111",Uncertain,Supported,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 2.1;placenta: 8.0,adipose tissue: 1.2,Not detected,,
51,CRLF1,"CISS, CISS1, CLF, CLF-1",ENSG00000006016,Cytokine receptor like factor 1,19,18572220-18607741,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041493, HPA041793",Approved,,,,Renal cancer:3.96e-4 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 17.2;placenta: 16.8,adipose tissue: 10.1,Group enriched,8.0,ASC diff: 706.3;Hep G2: 309.6
52,CSF2RA,"CD116, CSF2R",ENSG00000198223,Colony stimulating factor 2 receptor alpha subunit,X,1268800-1310381,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB016148,Uncertain,,,,"Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 93.3,appendix: 34.6,Group enriched,8.0,BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
53,CSF3R,"CD114, GCSFR",ENSG00000119535,Colony stimulating factor 3 receptor,1,36466043-36483278,"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB017116, HPA048086",Enhanced,,,,"Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)",Mixed,Tissue enhanced,,appendix: 211.2;bone marrow: 243.4;placenta: 147.9,spleen: 96.5,Cell line enhanced,,BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
54,CTHRC1,,ENSG00000164932,Collagen triple helix repeat containing 1,8,103371515-103382997,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA059806, HPA061896",Approved,,Approved,Nucleoplasm,"Renal cancer:1.22e-14 (unfavourable), Liver cancer:1.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 137.8;placenta: 125.5;urinary bladder: 100.0,breast: 49.2,Cell line enhanced,,ASC TERT1: 202.9;HHSteC: 162.6;HSkMC: 291.0;WM-115: 375.8
55,CXorf36,"DIA1R, FLJ14103",ENSG00000147113,Chromosome X open reading frame 36,X,45148374-45200901,"Disease related genes, Predicted secreted proteins",Evidence at transcript level,HPA002806,Uncertain,,,,,Expressed in all,Tissue enhanced,,placenta: 58.4,adipose tissue: 36.3,Cell line enriched,145.0,HUVEC TERT2: 67.8
56,CYSLTR2,"CysLT(2), CYSLT2R",ENSG00000152207,Cysteinyl leukotriene receptor 2,13,48653711-48711226,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046528,Uncertain,,,,,Group enriched,Tissue enhanced,,placenta: 36.7;seminal vesicle: 25.0,spleen: 11.4,Cell line enriched,64.0,HDLM-2: 83.3
57,CYTL1,"C17, C4orf4",ENSG00000170891,Cytokine like 1,4,5014586-5019472,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA067201,,,Supported,Nuclear membrane<br>Endoplasmic reticulum,"Stomach cancer:3.00e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable), Renal cancer:7.43e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,placenta: 64.9,seminal vesicle: 19.1,Cell line enhanced,,HEL: 171.3;HUVEC TERT2: 124.6;NB-4: 237.3;WM-115: 86.9
58,DACT2,"bA503C24.7, C6orf116, DAPPER2",ENSG00000164488,Dishevelled binding antagonist of beta catenin 2,6,168292830-168319754,Predicted intracellular proteins,Evidence at transcript level,"HPA030251, HPA030252",Approved,,,,"Endometrial cancer:1.07e-5 (favourable), Renal cancer:5.76e-5 (favourable)",Tissue enhanced,Tissue enhanced,,placenta: 18.8,prostate: 7.3,Group enriched,6.0,A549: 3.0;CACO-2: 2.2;EFO-21: 1.4;Hep G2: 1.0;hTCEpi: 1.3;NTERA-2: 2.3;SCLC-21H: 3.0
59,DIO3,TXDI3,ENSG00000197406,Iodothyronine deiodinase 3,14,101561351-101563452,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 27.8;placenta: 25.4",ovary: 6.2,Cell line enriched,37.0,AF22: 53.5
60,DKK1,"DKK-1, SK",ENSG00000107984,Dickkopf WNT signaling pathway inhibitor 1,10,52314296-52318042,Predicted secreted proteins,Evidence at protein level,,,,,,"Head and neck cancer:4.35e-8 (unfavourable), Lung cancer:7.80e-6 (unfavourable), Pancreatic cancer:1.27e-4 (unfavourable)",Mixed,Tissue enhanced,,"cervix, uterine: 56.5;placenta: 71.9",urinary bladder: 14.5,Cell line enhanced,,BJ: 975.2;CACO-2: 841.6;fHDF/TERT166: 1247.0
61,DLL4,,ENSG00000128917,Delta like canonical Notch ligand 4,15,40929340-40939072,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA023392,Uncertain,,,,Cervical cancer:3.97e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 28.6,lung: 16.4,Group enriched,14.0,BJ hTERT+: 48.7;HUVEC TERT2: 13.2;SCLC-21H: 37.4
62,DLX4,"BP1, DLX7, DLX8, DLX9",ENSG00000108813,Distal-less homeobox 4,17,49968970-49974959,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059933,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,placenta: 5.4,skin: 1.2,Cell line enhanced,,BEWO: 22.0;CACO-2: 13.7;HAP1: 11.5;K-562: 12.0
63,DLX5,,ENSG00000105880,Distal-less homeobox 5,7,97020392-97025097,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005670,Approved,,Approved,Nucleus,,Tissue enriched,Tissue enhanced,,endometrium: 20.2;placenta: 13.5;skin: 17.1,"cervix, uterine: 9.6",Group enriched,5.0,BEWO: 41.0;HAP1: 24.0
64,DLX6,,ENSG00000006377,Distal-less homeobox 6,7,97005548-97011039,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA030608, HPA061460",Uncertain,,Approved,Nuclear bodies,,Tissue enriched,Tissue enhanced,,endometrium: 4.4;placenta: 4.3;testis: 5.4,"cervix, uterine: 3.0",Cell line enhanced,,AN3-CA: 9.4;BEWO: 32.1;HAP1: 15.7;SCLC-21H: 8.6;SH-SY5Y: 11.6
65,DPRX,,ENSG00000204595,Divergent-paired related homeobox,19,53632056-53637009,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA043682,Uncertain,,,,,Tissue enriched,Tissue enhanced,,placenta: 1.8,"epididymis,testis: 0.5",Not detected,,
66,EDNRB,"ETB, HSCR, HSCR2",ENSG00000136160,Endothelin receptor type B,13,77895481-77919768,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB017842, HPA027546",Approved,,Supported,Plasma membrane<br>Cytosol,Renal cancer:7.20e-5 (favourable),Group enriched,Tissue enhanced,,placenta: 180.2,cerebral cortex: 88.8,Cell line enhanced,,AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
67,EGFLAM,"AGRINL, AGRNL, FLJ39155, PIKA",ENSG00000164318,"EGF like, fibronectin type III and laminin G domains",5,38258409-38465021,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:4.47e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 73.4,adipose tissue: 43.0,Cell line enhanced,,hTERT-HME1: 12.6;HUVEC TERT2: 13.4;LHCN-M2: 30.8;U-2 OS: 16.5
68,EGFR,"ERBB, ERBB1",ENSG00000146648,Epidermal growth factor receptor,7,55019021-55211628,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534",Enhanced,,Enhanced,Plasma membrane,Urothelial cancer:2.04e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 100.0,skin: 58.7,Cell line enriched,15.0,A-431: 4682.9
69,ELOVL2,Ssc2,ENSG00000197977,ELOVL fatty acid elongase 2,6,10980759-11044314,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Breast cancer:6.73e-5 (favourable),Group enriched,Tissue enhanced,,liver: 27.6;parathyroid gland: 36.7;placenta: 50.2,cerebral cortex: 22.8,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
70,ENPP1,"M6S1, NPPS, PC-1, PCA1, PDNP1",ENSG00000197594,Ectonucleotide pyrophosphatase/phosphodiesterase 1,6,131808016-131895155,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"CAB032904, HPA062066",Enhanced,,,,,Expressed in all,Tissue enhanced,,parathyroid gland: 54.3;placenta: 62.9,thyroid gland: 34.1,Cell line enhanced,,ASC diff: 23.4;U-138 MG: 27.3
71,FAM124B,FLJ22746,ENSG00000124019,Family with sequence similarity 124 member B,2,224378698-224402085,Predicted intracellular proteins,Evidence at protein level,HPA070240,Approved,,Approved,Nucleoplasm<br>Mitochondria,,Tissue enriched,Tissue enhanced,,parathyroid gland: 9.8;placenta: 12.5,"lung,smooth muscle: 3.6",Cell line enriched,7.0,HUVEC TERT2: 88.9
72,FAM156B,TMEM29B,ENSG00000179304,Family with sequence similarity 156 member B,X,52891306-52908560,Predicted intracellular proteins,Evidence at protein level,"HPA056640, HPA056643",Uncertain,,,,,Not detected,Tissue enhanced,,placenta: 46.8,skin: 24.9,Expressed in all,,
73,FAM162B,"bA86F4.2, C6orf189",ENSG00000183807,Family with sequence similarity 162 member B,6,116752197-116765723,Predicted membrane proteins,Evidence at protein level,"HPA036112, HPA060342",Enhanced,,,,Renal cancer:2.48e-4 (unfavourable),Tissue enriched,Tissue enhanced,,placenta: 94.0,lung: 27.0,Cell line enhanced,,BJ: 7.3;BJ hTERT+: 19.0;BJ hTERT+ SV40 Large T+ RasG12V: 21.4;HSkMC: 5.6
74,FAM184A,"C6orf60, FLJ13942",ENSG00000111879,Family with sequence similarity 184 member A,6,118959763-119149387,Predicted intracellular proteins,Evidence at protein level,"HPA034571, HPA034572, HPA041955",Uncertain,,Supported,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,placenta: 46.0;testis: 45.3,cerebral cortex: 25.1,Cell line enhanced,,AF22: 19.5;HEK93: 10.7;K-562: 15.2;SCLC-21H: 15.0
75,FBN1,"FBN, MASS, MFS1, OCTD, SGS, WMS",ENSG00000166147,Fibrillin 1,15,48408306-48645849,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002670, HPA017759, HPA021057, CAB058696, CAB068188",Enhanced,,Approved,Cytosol,"Renal cancer:7.44e-5 (unfavourable), Urothelial cancer:5.11e-4 (unfavourable), Stomach cancer:6.57e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 107.5,adipose tissue: 70.8,Cell line enhanced,,ASC TERT1: 315.9;fHDF/TERT166: 318.3;U-138 MG: 199.6;U-2197: 276.9
76,FCGR2A,"CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2",ENSG00000143226,Fc fragment of IgG receptor IIa,1,161505430-161524013,"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA010718, HPA014730",Enhanced,,,,Renal cancer:6.49e-7 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 160.6,appendix: 148.6,Cell line enhanced,,HEL: 26.6;HMC-1: 50.4;K-562: 16.0;THP-1: 42.6;U-937: 21.3
77,FN1,"CIG, FINC, GFND2, LETS, MSF",ENSG00000115414,Fibronectin 1,2,215360440-215436172,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB000126, HPA027066",Enhanced,,,,"Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 4284.3,lung: 1167.5,Cell line enhanced,,ASC TERT1: 24376.9;HSkMC: 11926.5;hTERT-HME1: 7509.7
78,GALNT15,"GALNT7, GALNTL2, pp-GalNAc-T15",ENSG00000131386,Polypeptide N-acetylgalactosaminyltransferase 15,3,16174649-16231992,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA017076,Uncertain,,Approved,Golgi apparatus<br>Cytosol,,Tissue enriched,Tissue enhanced,,adipose tissue: 36.3;cerebral cortex: 41.2;placenta: 43.0,breast: 18.3,Group enriched,11.0,ASC diff: 91.0;ASC TERT1: 90.9;HSkMC: 72.4;U-2197: 22.3
79,GDF15,"MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB",ENSG00000130513,Growth differentiation factor 15,19,18374731-18389176,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011191, CAB062554, HPA070957",Enhanced,,Enhanced,Golgi apparatus,,Expressed in all,Tissue enhanced,,placenta: 122.1;prostate: 74.5,kidney: 41.6,Cell line enhanced,,BEWO: 401.5;HHSteC: 474.6
80,GDF6,"BMP13, KFS, KFS1, SGM1",ENSG00000156466,Growth differentiation factor 6,8,96142330-96160792,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA045206,Uncertain,,Supported,Nucleoplasm<br>Nuclear membrane<br>Vesicles,Renal cancer:2.17e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,placenta: 15.1,gallbladder: 3.8,Cell line enriched,7.0,LHCN-M2: 27.7
81,GH1,"GH, GH-N, GHN, hGH-N",ENSG00000259384,Growth hormone 1,17,63917200-63918838,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA043715,Supported,,,,,Not detected,Tissue enhanced,,placenta: 1.2,duodenum: 0.6,Cell line enhanced,,U-698: 1.8
82,GJA3,"CX46, CZP3",ENSG00000121743,Gap junction protein alpha 3,13,20138255-20161049,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA014821,Supported,,,,,Tissue enhanced,Tissue enhanced,,heart muscle: 5.1;parathyroid gland: 5.9;placenta: 3.5,testis: 2.4,Cell line enhanced,,CAPAN-2: 6.8;HL-60: 5.2
83,GJA4,CX37,ENSG00000187513,Gap junction protein alpha 4,1,34792998-34795747,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047981,Approved,,,,"Liver cancer:3.28e-4 (favourable), Renal cancer:7.44e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 89.3,fallopian tube: 48.2,Cell line enriched,8.0,EFO-21: 70.4
84,GJA5,CX40,ENSG00000265107,Gap junction protein alpha 5,1,147756199-147773362,"Disease related genes, Predicted membrane proteins",Evidence at protein level,CAB013080,Uncertain,,,,,Expressed in all,Tissue enhanced,,placenta: 123.0,lung: 39.9,Cell line enriched,10.0,SK-BR-3: 100.3
85,GJC1,"CX45, GJA7",ENSG00000182963,Gap junction protein gamma 1,17,44798448-44830816,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071788,,,Uncertain,Nucleoli<br>Cell Junctions<br>Cytosol,"Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,endometrium: 44.3;placenta: 51.5;smooth muscle: 49.2,seminal vesicle: 27.2,Mixed,,
86,GLDC,"GCSP, NKH",ENSG00000178445,Glycine decarboxylase,9,6532464-6645783,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002318, HPA052887",Enhanced,,Supported,Nucleus<br>Mitochondria,"Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 30.3;liver: 19.9;placenta: 20.1,cerebral cortex: 10.6,Cell line enhanced,,BEWO: 206.9;RPTEC TERT1: 67.4
87,GPR1,,ENSG00000183671,G protein-coupled receptor 1,2,206175316-206218047,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010525,Uncertain,,Supported,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Mixed,Tissue enhanced,,placenta: 5.6,esophagus: 2.7,Cell line enhanced,,HHSteC: 112.4;hTCEpi: 44.7
88,GRAMD2,,ENSG00000175318,GRAM domain containing 2,15,72159807-72197785,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA029435,Uncertain,,Approved,Nucleoli<br>Nuclear speckles<br>Cytosol,Thyroid cancer:7.01e-4 (unfavourable),Mixed,Tissue enhanced,,epididymis: 43.8;placenta: 69.9,lung: 22.8,Group enriched,15.0,BEWO: 159.8;SK-BR-3: 56.9
89,GUCY1A2,"GC-SA2, GUC1A2",ENSG00000152402,Guanylate cyclase 1 soluble subunit alpha 2,11,106674012-107018524,"Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,CAB009534,Uncertain,,,,Renal cancer:3.02e-5 (unfavourable),Mixed,Tissue enhanced,,placenta: 25.6,endometrium: 21.1,Cell line enhanced,,BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
90,HACE1,KIAA1320,ENSG00000085382,HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1,6,104728093-104859919,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046071,,,Supported,Nuclear bodies<br>Endoplasmic reticulum,"Renal cancer:1.17e-5 (unfavourable), Thyroid cancer:7.50e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 44.1,testis: 19.1,Mixed,,
91,HES7,bHLHb37,ENSG00000179111,Hes family bHLH transcription factor 7,17,8120590-8124092,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA072105,Uncertain,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,placenta: 1.1,testis: 0.9,Cell line enhanced,,HAP1: 8.4;HDLM-2: 6.2;HeLa: 8.1
92,HIF3A,"bHLHe17, IPAS, MOP7, PASD7",ENSG00000124440,Hypoxia inducible factor 3 alpha subunit,19,46297046-46343433,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA041141,Approved,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,Endometrial cancer:6.90e-9 (unfavourable),Mixed,Tissue enhanced,,placenta: 39.8,spleen: 19.9,Cell line enhanced,,ASC TERT1: 6.5;HHSteC: 16.0;HSkMC: 12.2;TIME: 13.1
93,HMGCLL1,"bA418P12.1, DKFZP434G1411",ENSG00000146151,3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1,6,55434369-55579214,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 14.5;placenta: 9.0,prostate: 5.2,Cell line enriched,11.0,SCLC-21H: 7.1
94,HOXA13,"HOX1, HOX1J",ENSG00000106031,Homeobox A13,7,27193503-27200106,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5",rectum: 13.0,Cell line enhanced,,HAP1: 27.6;HEK93: 34.0;RT4: 33.4
95,HPGDS,"GSTS, GSTS1, GSTS1-1, H-PGDS, PGD2, PGDS",ENSG00000163106,Hematopoietic prostaglandin D synthase,4,94298535-94342876,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA024035,Enhanced,,,,,Mixed,Tissue enhanced,,placenta: 28.1,lung: 14.5,Group enriched,9.0,HEL: 43.7;HMC-1: 12.2
96,HSD17B2,"HSD17, SDR9C2",ENSG00000086696,Hydroxysteroid 17-beta dehydrogenase 2,16,82035004-82098534,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA021826, HPA050235",Enhanced,,Approved,Endoplasmic reticulum,Urothelial cancer:3.83e-4 (favourable),Tissue enhanced,Tissue enhanced,,duodenum: 430.9;placenta: 552.6,small intestine: 199.4,Cell line enhanced,,BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0
97,HSPA6,HSP70B',ENSG00000173110,Heat shock protein family A (Hsp70) member 6,1,161524540-161526910,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017452, HPA028549, HPA052504",Approved,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.98e-5 (unfavourable), Liver cancer:7.26e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 27.8,spleen: 15.1,Cell line enriched,7.0,Karpas-707: 36.1
98,HTR1B,"5-HT1B, 5-HT1DB, HTR1D2, S12",ENSG00000135312,5-hydroxytryptamine receptor 1B,6,77461753-77463773,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA028808,Enhanced,,Uncertain,Plasma membrane,,Mixed,Tissue enhanced,,placenta: 10.0;stomach: 4.7,cerebral cortex: 2.4,Group enriched,16.0,HUVEC TERT2: 68.8;TIME: 29.9
99,HTR1F,"5-HT1F, HTR1EL",ENSG00000179097,5-hydroxytryptamine receptor 1F,3,87990696-87993835,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA005555,Uncertain,,,,,Not detected,Tissue enhanced,,placenta: 2.7,cerebral cortex: 1.0,Cell line enhanced,,K-562: 1.1;LHCN-M2: 1.0
100,HYAL4,,ENSG00000106302,Hyaluronoglucosaminidase 4,7,123828983-123877478,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029453,Uncertain,,,,,Tissue enriched,Tissue enhanced,,placenta: 5.9;testis: 4.0,"skin,spleen: 1.1",Cell line enhanced,,BEWO: 3.5;CAPAN-2: 5.2;RT4: 11.2
101,IDO1,"IDO, INDO",ENSG00000131203,"Indoleamine 2,3-dioxygenase 1",8,39902275-39928444,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA023072, HPA023149, HPA027772, CAB072820",Enhanced,,,,"Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 149.4,lymph node: 57.3,Cell line enriched,7.0,EFO-21: 54.8
102,IGF2BP3,"CT98, IMP-3, IMP3",ENSG00000136231,Insulin like growth factor 2 mRNA binding protein 3,7,23310209-23470467,Predicted intracellular proteins,Evidence at protein level,HPA002037,Approved,,Enhanced,Cytosol,,Mixed,Tissue enhanced,,placenta: 41.6,testis: 9.3,Mixed,,
103,IGFBP3,"BP-53, IBP3",ENSG00000146674,Insulin like growth factor binding protein 3,7,45912245-45921874,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB010360,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 2671.0,endometrium: 886.0,Cell line enhanced,,fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3
104,IL12RB2,,ENSG00000081985,Interleukin 12 receptor subunit beta 2,1,67307364-67396900,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA024168,Uncertain,,Uncertain,Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,placenta: 11.8,cerebral cortex: 4.4,Cell line enhanced,,HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
105,IL1RAP,"C3orf13, IL-1RAcP, IL1R3",ENSG00000196083,Interleukin 1 receptor accessory protein,3,190514051-190659750,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035293,Uncertain,,Approved,Vesicles<br>Cytosol,"Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)",Expressed in all,Tissue enhanced,,liver: 113.0;placenta: 53.7,gallbladder: 19.8,Cell line enhanced,,SK-MEL-30: 193.6
106,IL2RB,"CD122, IL15RB",ENSG00000100385,Interleukin 2 receptor subunit beta,22,37125838-37175054,"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA062657,Enhanced,,,,"Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 52.7;spleen: 67.1,lymph node: 39.8,Cell line enriched,10.0,HDLM-2: 476.9
107,INS-IGF2,,ENSG00000129965,INS-IGF2 readthrough,11,2132538-2161209,Predicted secreted proteins,Evidence at protein level,CAB019430,Enhanced,,,,,Not detected,Tissue enhanced,,pancreas: 1.6;placenta: 3.3,"adrenal gland,endometrium: 0.5",Cell line enhanced,,SH-SY5Y: 1.3
108,JAM2,"C21orf43, CD322, JAM-B, JAMB, VE-JAM",ENSG00000154721,Junctional adhesion molecule 2,21,25639272-25717562,"CD markers, Predicted membrane proteins",Evidence at protein level,"HPA028789, HPA077346",,,Supported,Nucleoplasm<br>Plasma membrane,,Tissue enriched,Tissue enhanced,,placenta: 92.9,cerebral cortex: 34.2,Cell line enhanced,,AF22: 25.3;BJ hTERT+: 13.4;HDLM-2: 15.5;U-138 MG: 18.0;U-87 MG: 13.2
109,KANK4,"ANKRD38, KIAA0172",ENSG00000132854,KN motif and ankyrin repeat domains 4,1,62236979-62319414,Predicted intracellular proteins,Evidence at protein level,HPA014030,Uncertain,,Uncertain,Microtubules<br>Cytosol,,Mixed,Tissue enhanced,,parathyroid gland: 29.5;placenta: 16.4,adipose tissue: 11.8,Cell line enhanced,,BEWO: 32.2;Hep G2: 9.9;SCLC-21H: 7.5
110,KCNK3,"K2p3.1, TASK, TASK-1",ENSG00000171303,Potassium two pore domain channel subfamily K member 3,2,26692690-26733420,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,Renal cancer:2.37e-7 (unfavourable),Tissue enhanced,Tissue enhanced,,adrenal gland: 111.8;placenta: 35.8,lung: 19.9,Group enriched,6.0,EFO-21: 10.3;SCLC-21H: 30.6
111,KDR,"CD309, FLK1, VEGFR, VEGFR2",ENSG00000128052,Kinase insert domain receptor,4,55078477-55125589,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB004028,Enhanced,,Supported,Plasma membrane,Renal cancer:7.26e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 119.2,thyroid gland: 54.7,Group enriched,9.0,HUVEC TERT2: 178.6;TIME: 148.0
112,KLF14,BTEB5,ENSG00000266265,Kruppel like factor 14,7,130731235-130734061,Predicted intracellular proteins,Evidence at transcript level,HPA044729,Uncertain,,,,,Tissue enriched,Tissue enhanced,,placenta: 1.2,adipose tissue: 0.7,Cell line enhanced,,RH-30: 1.2
113,KRT23,"CK23, DKFZP434G032, HAIK1, K23, MGC26158",ENSG00000108244,Keratin 23,17,40922696-40937634,Predicted intracellular proteins,Evidence at protein level,"HPA012050, HPA016959, CAB017091",Approved,,Approved,Intermediate filaments<br>Cytosol,Urothelial cancer:8.26e-4 (unfavourable),Mixed,Tissue enhanced,,placenta: 68.6;skin: 70.9,salivary gland: 41.2,Group enriched,8.0,HBEC3-KT: 28.8;Hep G2: 17.3;T-47d: 63.7
114,L1TD1,"ECAT11, FLJ10884",ENSG00000240563,LINE1 type transposase domain containing 1,1,62194831-62212328,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,placenta: 16.6;testis: 11.0,appendix: 6.1,Cell line enriched,26.0,NTERA-2: 254.5
115,LAMA2,LAMM,ENSG00000196569,Laminin subunit alpha 2,6,128883141-129516569,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB040310, CAB078182",Enhanced,,,,Urothelial cancer:3.65e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 150.0,ovary: 49.5,Cell line enhanced,,ASC diff: 174.0;ASC TERT1: 126.8;HSkMC: 113.6
116,LAMB1,CLM,ENSG00000091136,Laminin subunit beta 1,7,107923799-108003255,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004056, HPA004132, CAB004256",Enhanced,,,,Liver cancer:2.07e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 263.7,adipose tissue: 161.4,Cell line enhanced,,HSkMC: 640.2
117,LAMC1,LAMB2,ENSG00000135862,Laminin subunit gamma 1,1,183023460-183145592,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001908, HPA001909, CAB004486, CAB078163",Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane,Urothelial cancer:8.85e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 332.9,smooth muscle: 147.5,Cell line enhanced,,ASC diff: 1091.5;HSkMC: 716.3
118,LAMC3,DKFZp434E202,ENSG00000050555,Laminin subunit gamma 3,9,131009082-131094473,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA022814,Enhanced,,,,,Mixed,Tissue enhanced,,placenta: 88.7,testis: 26.1,Cell line enhanced,,AF22: 5.3;EFO-21: 19.9;Hep G2: 5.5;SiHa: 8.5;U-2 OS: 6.9
119,LARGE2,"FLJ35207, GYLTL1B, PP5656",ENSG00000165905,LARGE xylosyl- and glucuronyltransferase 2,11,45921621-45929096,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA056621,Approved,,,,Renal cancer:3.04e-12 (favourable),Mixed,Tissue enhanced,,placenta: 52.7,parathyroid gland: 21.6,Cell line enhanced,,BEWO: 33.3;NTERA-2: 32.6;T-47d: 67.1
120,LGR5,"FEX, GPR49, GPR67, HG38",ENSG00000139292,Leucine rich repeat containing G protein-coupled receptor 5,12,71439770-71586310,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA012530,Approved,,,,Lung cancer:5.09e-4 (favourable),Group enriched,Tissue enhanced,,fallopian tube: 26.6;placenta: 26.9,seminal vesicle: 9.8,Group enriched,6.0,Hep G2: 25.0;SH-SY5Y: 110.2
121,LGSN,"GLULD1, LGS",ENSG00000146166,"Lengsin, lens protein with glutamine synthetase domain",6,63275951-63319977,Predicted intracellular proteins,Evidence at protein level,"HPA030957, HPA039983",Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Tissue enhanced,Tissue enhanced,,kidney: 2.8;liver: 2.4;placenta: 1.8,testis: 0.7,Cell line enhanced,,A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
122,LHX8,Lhx7,ENSG00000162624,LIM homeobox 8,1,75128434-75161533,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071806,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Not detected,Tissue enhanced,,placenta: 1.8;testis: 1.3;tonsil: 1.5,"gallbladder,urinary bladder: 1.0",Group enriched,6.0,SCLC-21H: 30.2;U-266/70: 6.6
123,LYPD6,MGC52057,ENSG00000187123,LY6/PLAUR domain containing 6,2,149329985-149474148,Predicted secreted proteins,Evidence at protein level,HPA042805,Uncertain,,Approved,Cytosol,"Urothelial cancer:2.72e-4 (favourable), Ovarian cancer:3.59e-4 (favourable)",Mixed,Tissue enhanced,,gallbladder: 17.3;placenta: 22.5,breast: 12.0,Cell line enhanced,,AN3-CA: 33.5;fHDF/TERT166: 36.6;LHCN-M2: 38.4;RT4: 30.7
124,LYVE1,"LYVE-1, XLKD1",ENSG00000133800,Lymphatic vessel endothelial hyaluronan receptor 1,11,10556966-10611689,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"CAB025860, HPA042953",Supported,,,,"Renal cancer:6.98e-5 (unfavourable), Ovarian cancer:1.07e-4 (unfavourable)",Mixed,Tissue enhanced,,adipose tissue: 157.5;placenta: 213.1,smooth muscle: 95.3,Cell line enriched,11.0,HUVEC TERT2: 67.8
125,MAP1LC3C,ATG8J,ENSG00000197769,Microtubule associated protein 1 light chain 3 gamma,1,241995490-241999073,Predicted intracellular proteins,Evidence at protein level,HPA072670,,,Supported,Cytoplasmic bodies,Endometrial cancer:1.34e-7 (unfavourable),Mixed,Tissue enhanced,,breast: 12.7;placenta: 16.1,lung: 8.1,Cell line enhanced,,AF22: 6.0;ASC TERT1: 3.9;BEWO: 3.7;EFO-21: 3.2
126,MATN3,"EDM5, HOA",ENSG00000132031,Matrilin 3,2,19992111-20012694,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA051250,,,Approved,Endoplasmic reticulum<br>Golgi apparatus,"Stomach cancer:4.74e-5 (unfavourable), Liver cancer:8.62e-5 (unfavourable), Cervical cancer:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 20.2;placenta: 16.5,seminal vesicle: 6.2,Cell line enriched,5.0,Hep G2: 98.9
127,MEOX2,"GAX, MOX2",ENSG00000106511,Mesenchyme homeobox 2,7,15611212-15686812,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA053793,Enhanced,,,,,Tissue enriched,Tissue enhanced,,adipose tissue: 28.5;placenta: 57.7,lung: 10.8,Cell line enhanced,,AN3-CA: 217.5;SCLC-21H: 37.0;U-138 MG: 58.7
128,MKRN3,"D15S9, MGC88288, RNF63, ZFP127, ZNF127",ENSG00000179455,Makorin ring finger protein 3,15,23565678-23630075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029494,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Glioma:9.23e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 5.9;placenta: 4.1;testis: 3.6,epididymis: 1.1,Cell line enhanced,,K-562: 22.8
129,MS4A4A,"CD20L1, MS4A4, MS4A7",ENSG00000110079,Membrane spanning 4-domains A4A,11,60280541-60308972,Predicted membrane proteins,Evidence at transcript level,HPA029323,Approved,,,,,Expressed in all,Tissue enhanced,,placenta: 102.2,adipose tissue: 63.4,Cell line enriched,24.0,K-562: 118.6
130,MSX2,"CRS2, FPP, HOX8, MSH, PFM, PFM1",ENSG00000120149,Msh homeobox 2,5,174724533-174730893,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005652,Uncertain,,Supported,Nuclear speckles,"Endometrial cancer:8.43e-5 (favourable), Lung cancer:6.93e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 47.8,parathyroid gland: 16.4,Cell line enriched,7.0,BEWO: 311.1
131,MTNR1B,,ENSG00000134640,Melatonin receptor 1B,11,92969720-92985066,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,placenta: 1.4,testis: 0.8,Not detected,,
132,MYCN,"bHLHe37, MYCNOT, N-myc, NMYC",ENSG00000134323,V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog,2,15940564-15947007,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057420,,,Approved,Nucleus<br>Nucleoli,,Tissue enhanced,Tissue enhanced,,placenta: 13.7,cerebral cortex: 7.2,Cell line enhanced,,AF22: 43.5;BEWO: 230.1;HMC-1: 50.4;NTERA-2: 91.1;RH-30: 61.3
133,MYO7A,"DFNA11, DFNB2, NSRD2, USH1B",ENSG00000137474,Myosin VIIA,11,77128264-77215239,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028918, CAB034059",Uncertain,,Approved,Cytosol,Renal cancer:3.07e-4 (unfavourable),Expressed in all,Tissue enhanced,,adrenal gland: 26.8;placenta: 20.8,testis: 17.2,Cell line enhanced,,BEWO: 11.1;RH-30: 20.1;RPMI-8226: 9.7;SK-BR-3: 8.1;U-937: 11.1
134,N4BP3,LZTS4,ENSG00000145911,NEDD4 binding protein 3,5,178113443-178126087,Predicted intracellular proteins,Evidence at protein level,"HPA030972, HPA030973, HPA061387",Approved,,Supported,Nucleoplasm<br>Centrosome,Renal cancer:2.38e-4 (favourable),Mixed,Tissue enhanced,,placenta: 11.8,parathyroid gland: 10.2,Cell line enhanced,,MCF7: 15.8;RH-30: 19.3;SK-BR-3: 53.2
135,NDNF,"C4orf31, FLJ23191",ENSG00000173376,Neuron derived neurotrophic factor,4,121035613-121073021,Predicted secreted proteins,Evidence at protein level,HPA048881,,,Supported,Vesicles,Renal cancer:3.26e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,lung: 159.9;placenta: 86.6,ovary: 52.7,Cell line enhanced,,fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4
136,NFE2L3,Nrf3,ENSG00000050344,"Nuclear factor, erythroid 2 like 3",7,26152240-26187125,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA055889,Enhanced,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:7.58e-12 (unfavourable), Pancreatic cancer:6.62e-5 (unfavourable), Stomach cancer:2.14e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 50.3,appendix: 14.3,Cell line enhanced,,BEWO: 132.0;NTERA-2: 115.5
137,NID2,,ENSG00000087303,Nidogen 2,14,52004803-52069228,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA052460, HPA058772",Enhanced,,Supported,Plasma membrane,"Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 88.5,thyroid gland: 54.1,Cell line enhanced,,ASC diff: 198.6;BJ: 133.5;HHSteC: 134.5;HSkMC: 435.7
138,NPFFR2,"GPR74, NPFF2, NPGPR",ENSG00000056291,Neuropeptide FF receptor 2,4,72031804-72148067,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA026825,,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,placenta: 2.3;seminal vesicle: 4.6,epididymis: 1.1,Group enriched,11.0,NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
139,NRK,DKFZp686A17109,ENSG00000123572,Nik related kinase,X,105822543-105958610,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017238,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,ovary: 39.8;placenta: 34.3,adrenal gland: 21.0,Cell line enhanced,,fHDF/TERT166: 45.0;RH-30: 12.4;RPTEC TERT1: 26.3
140,OPN3,"ECPN, encephalopsin, ERO, NMO-1, PPP1R116",ENSG00000054277,Opsin 3,1,241590102-241677376,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB013682, HPA064443",Uncertain,,Approved,Nucleoplasm,"Cervical cancer:3.17e-5 (unfavourable), Glioma:2.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 26.9,lung: 12.8,Cell line enhanced,,ASC TERT1: 51.2
141,OR51E1,"GPR136, GPR164, OR51E1P, OR52A3P",ENSG00000180785,Olfactory receptor family 51 subfamily E member 1,11,4643420-4655488,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,"CAB019995, HPA051439",Approved,,,,Renal cancer:1.23e-6 (unfavourable),Tissue enriched,Tissue enhanced,,adipose tissue: 6.4;placenta: 9.6;prostate: 9.0,"smooth muscle,urinary bladder: 1.7",Cell line enriched,96.0,SCLC-21H: 10.5
142,P2RY1,P2Y1,ENSG00000169860,Purinergic receptor P2Y1,3,152834693-152841439,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA015577,Enhanced,,,,Renal cancer:2.04e-7 (unfavourable),Mixed,Tissue enhanced,,placenta: 34.0,esophagus: 19.9,Cell line enriched,6.0,HEL: 38.5
143,P2RY14,"GPR105, KIAA0001",ENSG00000174944,Purinergic receptor P2Y14,3,151212117-151278467,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,CAB022646,Uncertain,,,,Renal cancer:1.72e-5 (unfavourable),Mixed,Tissue enhanced,,placenta: 45.9,esophagus: 23.3,Cell line enriched,77.0,HMC-1: 60.0
144,P2RY6,P2Y6,ENSG00000171631,Pyrimidinergic receptor P2Y6,11,73264505-73298617,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB022740,Uncertain,,,,Renal cancer:2.50e-7 (unfavourable),Mixed,Tissue enhanced,,placenta: 16.8;spleen: 35.6,appendix: 10.8,Cell line enhanced,,AN3-CA: 64.0;EFO-21: 20.2;MCF7: 25.4;SK-BR-3: 41.5
145,P3H1,"GROS1, LEPRE1, LEPRECAN, MGC117314",ENSG00000117385,Prolyl 3-hydroxylase 1,1,42746335-42767084,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA012113, HPA016980",Approved,,Approved,Nucleoli<br>Vesicles,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 53.5,smooth muscle: 28.8,Expressed in all,,
146,PABPC4L,,ENSG00000254535,Poly(A) binding protein cytoplasmic 4 like,4,134196333-134201748,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:1.11e-5 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 12.8;placenta: 14.7,endometrium: 6.4,Cell line enhanced,,HAP1: 11.9;HeLa: 10.3;REH: 7.4;RH-30: 8.3;U-2 OS: 9.1
147,PCDH12,VE-cadherin-2,ENSG00000113555,Protocadherin 12,5,141943585-141969741,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA051242,Uncertain,,,,Renal cancer:2.56e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 38.5,spleen: 22.5,Cell line enhanced,,HUVEC TERT2: 19.4;Karpas-707: 41.2;U-937: 7.5
148,PCOLCE2,PCPE2,ENSG00000163710,Procollagen C-endopeptidase enhancer 2,3,142815922-142889203,Predicted secreted proteins,Evidence at protein level,HPA013203,Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.96e-5 (unfavourable), Urothelial cancer:1.08e-4 (unfavourable)",Mixed,Tissue enhanced,,adipose tissue: 81.7;placenta: 57.9,heart muscle: 42.3,Cell line enhanced,,ASC diff: 37.5;U-2197: 58.5;U-266/70: 47.2
149,PDE6H,,ENSG00000139053,Phosphodiesterase 6H,12,14973022-14981865,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045118,Supported,,,,,Not detected,Tissue enhanced,,bone marrow: 2.4;placenta: 1.3,adrenal gland: 0.5,Not detected,,
150,PDGFB,"SIS, SSV",ENSG00000100311,Platelet derived growth factor subunit B,22,39223359-39244751,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB011604, HPA011972, CAB018341",Supported,,Approved,Vesicles,Lung cancer:3.67e-5 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 59.7,lung: 28.6,Cell line enhanced,,EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5
151,PDPN,"aggrus, Gp38, GP40, PA2.26, T1A-2",ENSG00000162493,Podoplanin,1,13583465-13617957,Predicted membrane proteins,Evidence at protein level,"HPA007534, CAB008376",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,placenta: 194.0,appendix: 78.6,Cell line enhanced,,AF22: 148.2;EFO-21: 336.7;HAP1: 260.6;HHSteC: 181.4;TIME: 199.2
152,PEG3,"KIAA0287, ZKSCAN22, ZNF904, ZSCAN24",ENSG00000198300,Paternally expressed 3,19,56810083-56840728,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA026070,Approved,,Supported,Nucleoplasm,Thyroid cancer:1.56e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,ovary: 340.4;placenta: 197.8,adrenal gland: 102.0,Cell line enhanced,,BEWO: 100.6;Hep G2: 150.6;RH-30: 70.4
153,PGF,"D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760",ENSG00000119630,Placental growth factor,14,74941834-74955784,"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA041624,,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,"Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 71.1;thyroid gland: 64.5,"cervix, uterine: 30.1",Group enriched,6.0,BEWO: 398.0;HUVEC TERT2: 164.7
154,PITX2,"ARP1, Brx1, IGDS, IHG2, IRID2, Otlx2, RGS, RIEG, RIEG1, RS",ENSG00000164093,Paired like homeodomain 2,4,110617423-110642123,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA050074, HPA062728",,,Enhanced,Nucleus,,Mixed,Tissue enhanced,,placenta: 72.2,skeletal muscle: 18.3,Cell line enhanced,,CACO-2: 23.3;LHCN-M2: 25.4;RH-30: 24.6
155,PKIB,PRKACN2,ENSG00000135549,CAMP-dependent protein kinase inhibitor beta,6,122471917-122726373,Predicted intracellular proteins,Evidence at protein level,HPA030156,Approved,,,,"Renal cancer:2.47e-7 (favourable), Liver cancer:4.72e-7 (unfavourable)",Expressed in all,Tissue enhanced,,colon: 89.1;placenta: 85.4,parathyroid gland: 78.0,Cell line enhanced,,AF22: 71.0;PC-3: 106.9;RPTEC TERT1: 141.0;SCLC-21H: 186.3
156,PODNL1,"FLJ23447, SLRR5B",ENSG00000132000,Podocan like 1,19,13931187-13953392,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042807,Approved,,,,"Glioma:2.06e-8 (unfavourable), Urothelial cancer:4.49e-4 (unfavourable)",Mixed,Tissue enhanced,,placenta: 12.3,skin: 8.5,Cell line enhanced,,HSkMC: 17.5;SiHa: 21.2;U-2 OS: 16.8
157,POU6F2,RPF-1,ENSG00000106536,POU class 6 homeobox 2,7,38977998-39493095,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 3.1;placenta: 1.8,"gallbladder,testis: 1.2",Cell line enhanced,,EFO-21: 3.0;NTERA-2: 3.1;T-47d: 5.3;U-266/70: 4.7;U-266/84: 5.5
158,PRDM6,"KMT8C, PRISM",ENSG00000061455,PR/SET domain 6,5,123089121-123194266,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA030322, HPA030324",Uncertain,,Uncertain,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 5.2;placenta: 5.9,lung: 4.0,Cell line enhanced,,BEWO: 3.5;HEK93: 4.7
159,PRLR,,ENSG00000113494,Prolactin receptor,5,35048756-35230589,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,placenta: 70.9,kidney: 33.1,Cell line enriched,22.0,T-47d: 356.8
160,PSG7,,ENSG00000221878,Pregnancy specific beta-1-glycoprotein 7 (gene/pseudogene),19,42924132-42937178,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046327,Approved,,,,,Not detected,Tissue enhanced,,placenta: 5.8;skin: 1.4,smooth muscle: 0.9,Cell line enhanced,,BJ: 1.3;HBF TERT88: 2.2;U-2197: 1.7
161,PTGES,"MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12",ENSG00000148344,Prostaglandin E synthase,9,129738331-129753047,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045064,Enhanced,,Supported,Endoplasmic reticulum,"Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 82.9;seminal vesicle: 119.5,urinary bladder: 36.3,Cell line enhanced,,BEWO: 155.0;HaCaT: 189.3;U-2197: 372.3
162,REN,,ENSG00000143839,Renin,1,204154819-204190324,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005131, CAB025903",Approved,,,,Renal cancer:6.45e-5 (unfavourable),Tissue enriched,Tissue enhanced,,kidney: 51.2;placenta: 21.0,endometrium: 8.9,Cell line enhanced,,BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
163,RGPD2,"RANBP2L2, RGP2",ENSG00000185304,RANBP2-like and GRIP domain containing 2,2,87755955-87825952,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,,Approved,Nuclear membrane<br>Vesicles,,Not detected,Tissue enhanced,,placenta: 14.3;testis: 33.3,bone marrow: 6.3,Cell line enhanced,,BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7
164,RP11-638I8.1,,ENSG00000283247,,7,45860008-45873082,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,placenta: 1.2,breast: 0.8,Not detected,,
165,RP11-872D17.8,,ENSG00000254979,,11,57387365-57424059,Predicted membrane proteins,Evidence at protein level,HPA038515,Supported,,,,,Mixed,Tissue enhanced,,bone marrow: 7.7;placenta: 10.5,skin: 5.8,Cell line enriched,7.0,HMC-1: 162.8
166,RSPO2,MGC35555,ENSG00000147655,R-spondin 2,8,107899316-108083648,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA024764, CAB025900, HPA053068",Approved,,,,,Mixed,Tissue enhanced,,cerebral cortex: 20.2;placenta: 25.7,prostate: 15.8,Cell line enhanced,,HEK93: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2
167,S1PR2,"AGR16, DFNB68, EDG5, Gpcr13, H218",ENSG00000267534,Sphingosine-1-phosphate receptor 2,19,10221435-10231272,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA014255, HPA014307",Approved,,Uncertain,Nuclear speckles<br>Golgi apparatus,Renal cancer:4.36e-10 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 27.0,lymph node: 13.3,Cell line enhanced,,Daudi: 38.8;U-698: 40.3;WM-115: 38.8
168,SCIN,KIAA1905,ENSG00000006747,Scinderin,7,12570577-12660179,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020518, HPA024264",Enhanced,,Enhanced,Plasma membrane,Renal cancer:4.26e-8 (favourable),Tissue enhanced,Tissue enhanced,,placenta: 110.4,kidney: 52.0,Cell line enhanced,,RPTEC TERT1: 71.2;SK-BR-3: 76.9
169,SCN11A,"NaN, Nav1.9, SCN12A, SNS-2",ENSG00000168356,Sodium voltage-gated channel alpha subunit 11,3,38845769-38950561,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA036746, HPA036747",Uncertain,,,,,Not detected,Tissue enhanced,,placenta: 3.7;spleen: 5.3,testis: 2.0,Cell line enhanced,,HDLM-2: 1.1
170,SEMA6D,"FLJ11598, KIAA1479",ENSG00000137872,Semaphorin 6D,15,47184101-47774223,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA043109,,,Approved,Golgi apparatus<br>Plasma membrane,Renal cancer:5.96e-5 (favourable),Tissue enhanced,Tissue enhanced,,placenta: 63.6,small intestine: 44.3,Cell line enhanced,,BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
171,SERPINB9,"CAP3, PI9",ENSG00000170542,Serpin family B member 9,6,2887266-2903280,Predicted intracellular proteins,Evidence at protein level,HPA030067,Uncertain,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.66e-6 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 74.8,appendix: 48.4,Cell line enhanced,,BEWO: 219.1;U-698: 69.6
172,SERPINE1,"PAI, PAI1, PLANH1",ENSG00000106366,Serpin family E member 1,7,101127089-101139266,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA050039, CAB068501",Uncertain,,Approved,Cytosol,"Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 580.3;placenta: 600.2,adipose tissue: 215.8,Cell line enhanced,,TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
173,SLC16A10,"MCT10, TAT1",ENSG00000112394,Solute carrier family 16 member 10,6,111087503-111231194,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA016860,Approved,,Approved,Vesicles<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,placenta: 38.6,skin: 22.4,Cell line enhanced,,HAP1: 53.9;HEK93: 20.6;RPMI-8226: 30.8
174,SLC19A3,THTR2,ENSG00000135917,Solute carrier family 19 member 3,2,227685210-227718012,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038898,Approved,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,adipose tissue: 50.2;placenta: 35.3,duodenum: 12.3,Cell line enhanced,,ASC diff: 6.9;BEWO: 6.1;CACO-2: 12.7
175,SLC2A1,"CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR",ENSG00000117394,Solute carrier family 2 member 1,1,42925375-42959173,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002759, HPA031345, HPA058494",Enhanced,Supported,Enhanced,Plasma membrane,"Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 293.0,skin: 59.3,Expressed in all,,
176,SLC43A2,MGC34680,ENSG00000167703,Solute carrier family 43 member 2,17,1569267-1628886,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA021564,Enhanced,,,,"Pancreatic cancer:1.05e-6 (favourable), Renal cancer:5.40e-5 (favourable)",Expressed in all,Tissue enhanced,,placenta: 31.7,appendix: 17.0,Cell line enhanced,,CACO-2: 14.8
177,SLC6A2,"NAT1, NET, NET1, SLC6A5",ENSG00000103546,Solute carrier family 6 member 2,16,55655604-55706192,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004057, HPA076311, CAB078195",Enhanced,Supported,Approved,Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,adrenal gland: 29.2;placenta: 18.4;skin: 15.7,testis: 11.4,Cell line enriched,35.0,SH-SY5Y: 519.4
178,SMAGP,"hSMAGP, MGC149453, MGC149454",ENSG00000170545,Small cell adhesion glycoprotein,12,51244558-51270890,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039711,Enhanced,,Supported,Nucleoplasm<br>Plasma membrane,"Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 145.7,esophagus: 83.3,Cell line enhanced,,BEWO: 126.2
179,SOX7,,ENSG00000171056,SRY-box 7,8,10723768-10730512,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA009065,Approved,,Approved,Nuclear speckles<br>Golgi apparatus,,Expressed in all,Tissue enhanced,,placenta: 49.6,lung: 18.7,Cell line enhanced,,HaCaT: 21.1;HUVEC TERT2: 46.6;TIME: 36.3
180,SP6,"Epfn, KLF14",ENSG00000189120,Sp6 transcription factor,17,47844908-47855874,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA024516, HPA044469",,,Supported,Nucleoplasm<br>Mitotic spindle<br>Centrosome,"Lung cancer:2.11e-6 (unfavourable), Urothelial cancer:5.72e-4 (favourable), Stomach cancer:6.39e-4 (favourable)",Mixed,Tissue enhanced,,placenta: 32.5;seminal vesicle: 14.7,skin: 7.2,Cell line enriched,5.0,BEWO: 88.4
181,SPP1,"BNSP, BSPI, ETA-1, OPN",ENSG00000118785,Secreted phosphoprotein 1,4,87975650-87983426,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002212, HPA027540, HPA027541",Enhanced,,Supported,Golgi apparatus,"Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7,cerebral cortex: 795.2,Group enriched,6.0,EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5
182,STRA6,FLJ12541,ENSG00000137868,Stimulated by retinoic acid 6,15,74179466-74212267,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA040839,Approved,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,"cervix, uterine: 37.0;placenta: 20.4",endometrium: 13.2,Cell line enhanced,,CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5
183,STS,"ARSC, ARSC1",ENSG00000101846,Steroid sulfatase,X,7219456-7354810,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA002904,Enhanced,,,,Pancreatic cancer:3.47e-4 (unfavourable),Expressed in all,Tissue enhanced,,placenta: 36.5,adipose tissue: 18.9,Cell line enhanced,,U-266/70: 79.0
184,SVEP1,"bA427L11.3, C9orf13, FLJ13529, POLYDOM",ENSG00000165124,"Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1",9,110365251-110579880,Predicted secreted proteins,Evidence at protein level,"HPA020610, HPA021520",Uncertain,,,,Stomach cancer:8.33e-4 (unfavourable),Mixed,Tissue enhanced,,placenta: 87.2,adipose tissue: 36.7,Cell line enhanced,,ASC diff: 101.0;ASC TERT1: 59.3;BJ hTERT+: 50.6;HHSteC: 45.2;HSkMC: 48.5
185,TCF21,"bHLHa23, POD1",ENSG00000118526,Transcription factor 21,6,133889138-133895553,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA013189,Uncertain,,,,,Mixed,Tissue enhanced,,placenta: 62.4;spleen: 46.9,ovary: 32.1,Cell line enriched,10.0,HHSteC: 13.5
186,TCHH,THH,ENSG00000159450,Trichohyalin,1,152106317-152115454,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028375,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,placenta: 1.6;spleen: 2.1,testis: 1.2,Cell line enhanced,,HaCaT: 3.2;SCLC-21H: 1.3;THP-1: 1.3
187,TCTEX1D1,FLJ40873,ENSG00000152760,Tctex1 domain containing 1,1,66752459-66778787,Predicted intracellular proteins,Evidence at protein level,HPA028420,Uncertain,,,,,Tissue enriched,Tissue enhanced,,fallopian tube: 16.6;placenta: 9.6,liver: 4.0,Group enriched,6.0,HEL: 14.3;HUVEC TERT2: 13.0;THP-1: 12.0
188,TEK,"CD202b, TIE-2, TIE2, VMCM, VMCM1",ENSG00000120156,TEK receptor tyrosine kinase,9,27109141-27230175,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB010359, HPA073265",Approved,,Supported,Plasma membrane<br>Microtubule organizing center,"Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 65.9,lung: 42.6,Group enriched,8.0,HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
189,TENM3,"KIAA1455, ODZ3, Ten-M3",ENSG00000218336,Teneurin transmembrane protein 3,4,182143987-182803024,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047043,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,placenta: 18.7,parathyroid gland: 13.4,Cell line enhanced,,HDLM-2: 83.6;T-47d: 80.9
190,TFAP2A,"AP-2, AP2TF, TFAP2",ENSG00000137203,Transcription factor AP-2 alpha,6,10393186-10419659,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000326, HPA028850, HPA056871",Enhanced,,Enhanced,Nucleoplasm,Lung cancer:1.09e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,breast: 40.0;placenta: 42.3;skin: 76.1,epididymis: 24.9,Cell line enhanced,,HDLM-2: 103.3
191,TIE1,"JTK14, TIE",ENSG00000066056,Tyrosine kinase with immunoglobulin like and EGF like domains 1,1,43300993-43323108,"Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,placenta: 70.6,lung: 40.1,Cell line enhanced,,EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
192,TIMP3,SFD,ENSG00000100234,TIMP metallopeptidase inhibitor 3,22,32801701-32863043,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,"Ovarian cancer:1.90e-5 (unfavourable), Renal cancer:1.50e-4 (favourable)",Mixed,Tissue enhanced,,placenta: 1439.9,adipose tissue: 729.9,Cell line enhanced,,BJ: 988.6;fHDF/TERT166: 830.6;WM-115: 879.2
193,TINAGL1,"ARG1, LCN7, LIECG3, P3ECSL, TINAGRP",ENSG00000142910,Tubulointerstitial nephritis antigen like 1,1,31576485-31587686,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048695,Approved,,,,"Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 268.9,adipose tissue: 102.6,Cell line enhanced,,BEWO: 313.9;EFO-21: 383.9;TIME: 309.9
194,TLL1,,ENSG00000038295,Tolloid like 1,4,165873258-166103895,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA060767,,,Approved,Vesicles,,Mixed,Tissue enhanced,,placenta: 10.5,gallbladder: 4.4,Cell line enhanced,,HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
195,TMEM100,"FLJ10970, FLJ37856",ENSG00000166292,Transmembrane protein 100,17,55719627-55732121,Predicted membrane proteins,Evidence at protein level,HPA055936,Approved,,Uncertain,Nucleoplasm,"Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)",Mixed,Tissue enhanced,,lung: 131.2;placenta: 78.3,epididymis: 44.5,Cell line enhanced,,ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8
196,TRPC6,"FSGS2, TRP6",ENSG00000137672,Transient receptor potential cation channel subfamily C member 6,11,101451564-101872562,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA045098, HPA062164",Approved,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,placenta: 30.1,lung: 20.0,Cell line enhanced,,A549: 4.4;ASC diff: 6.0;BJ hTERT+: 3.9;HEL: 4.3;RPTEC TERT1: 16.5
197,UBASH3B,"KIAA1959, STS-1, TULA2",ENSG00000154127,Ubiquitin associated and SH3 domain containing B,11,122655675-122814473,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA038605, HPA038607",Approved,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,placenta: 19.6;spleen: 21.3,lung: 6.7,Cell line enhanced,,HEL: 108.5;HMC-1: 77.6
198,USP27X,USP27,ENSG00000273820,"Ubiquitin specific peptidase 27, X-linked",X,49879948-49882565,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA077264,,,Approved,Nucleoplasm<br>Vesicles,"Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)",Expressed in all,Tissue enhanced,,placenta: 19.7,cerebral cortex: 10.3,Mixed,,
199,VCAN,"CSPG2, PG-M",ENSG00000038427,Versican,5,83471465-83582303,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004726, CAB008979",Enhanced,,Supported,Vesicles,"Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 105.5;placenta: 104.6,smooth muscle: 67.1,Cell line enhanced,,AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9
200,VGLL3,VGL-3,ENSG00000206538,Vestigial like family member 3,3,86876388-86991119,Predicted intracellular proteins,Evidence at protein level,HPA054983,Approved,,Approved,Nucleoli<br>Cytosol,,Tissue enhanced,Tissue enhanced,,placenta: 57.8,adipose tissue: 24.4,Cell line enriched,5.0,U-2197: 482.9
201,VSTM5,"C11orf90, LOC387804",ENSG00000214376,V-set and transmembrane domain containing 5,11,93818232-93850531,Predicted membrane proteins,Evidence at transcript level,"HPA029525, HPA063591",Uncertain,,Uncertain,Endoplasmic reticulum,,Mixed,Tissue enhanced,,placenta: 6.5,cerebral cortex: 2.8,Cell line enhanced,,HaCaT: 1.1;PC-3: 5.1;SH-SY5Y: 2.3
202,WFDC1,PS20,ENSG00000103175,WAP four-disulfide core domain 1,16,84294646-84329851,Predicted secreted proteins,Evidence at transcript level,HPA031411,Uncertain,,,,,Mixed,Tissue enhanced,,placenta: 121.8;seminal vesicle: 135.6,prostate: 88.4,Cell line enhanced,,AN3-CA: 24.0;BJ: 15.1;HEL: 13.6;HeLa: 16.0
203,WNT6,,ENSG00000115596,Wnt family member 6,2,218859821-218874233,Predicted secreted proteins,Evidence at protein level,HPA070759,Approved,,,,,Tissue enhanced,Tissue enhanced,,placenta: 2.9,spleen: 1.5,Cell line enriched,6.0,BEWO: 33.5
204,WNT7A,,ENSG00000154764,Wnt family member 7A,3,13816258-13880121,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA015719, CAB025894",Approved,,,,"Pancreatic cancer:3.03e-6 (unfavourable), Endometrial cancer:2.96e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.7;gallbladder: 3.6;placenta: 3.9,lung: 3.0,Group enriched,5.0,BEWO: 56.9;EFO-21: 52.0;PC-3: 18.2;RPTEC TERT1: 74.6
